synthetic peptide raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-04-09. Anything still debated is marked as such rather than presented as settled.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
| Property | Value | Notes |
|---|---|---|
| Common name | AOD-9604 | Development code used in scientific literature. |
| Chemical class | Synthetic peptide | Fragment of human growth hormone. |
| Amino acid length | 16 residues | Matches hGH region 176-191. |
| Appearance | White to off-white powder | Typical lyophilized peptide solid. |
| Solubility | Soluble in water | Dissolves in aqueous media; exact behavior depends on salt form. |
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
== Religious customs == Jewish and Muslim dietary laws require the removal of blood from freshly slaughtered meat. Salt and brine are used for the purpose in both traditions, but salting is more common in Kosher Shechita (where it is all but required) than in Halal Dhabiha (as in most cases, draining alone will suffice).
And although such interventions were later found to be ineffective for their intended purposes, those works led to the creation of tissue engineering, techniques for cardiopulmonary bypass and dialysis, established the foundation for the technologies for storing organs extracted from a person outside the body (which now are used, for example, during organ donation), the emergence of cryobiology. 1920s–1930s In medical practice, sex gland transplants were introduced to obtain rejuvenating effects. (Though separate experiments in this direction were done even earlier, even in antiquity.) The earlier mentioned operations of Dr. Frank Lydston in 1914 remained almost unnoticed. But the works of Leo Leonidas Stanley quickly received widespread scientific notice. Stanley was a physician at a prison in California and began to do these operations since 1919, using glands of executed criminals. In the following years, such operations were done by dozens of physicians (including Eugen Steinach) but they became most famous due to the activity of the French surgeon of Russian extraction Serge/Samuel Voronoff. It was believed that transplantation of sex glands provides more durable effects than injection of a suspension of ground glands. In case of transplantation from human to human, the glands of executed criminals were usually used. But due to a shortage of materials, the sex glands of young healthy monkeys were widely used, which were specially grown for this purpose (usually thin sections of the glands were implanted).
ubiquitination Also ubiquitylation. The labelling of a biomolecule (often another protein) by covalently attaching a ubiquitin protein to it—generally via the formation of an amide bond between the ubiquitin's C-terminal glycine and positively charged side chains (often lysine or arginine residues) of the labelled molecule, an ATP-dependent reaction catalyzed by ubiquitin-conjugating enzymes—thus making it identifiable to molecules capable of recognizing ubiquitin epitopes. Ubiquitination is a widely used post-translational modification by which proteins are tagged; the attachment of a single ubiquitin molecule (monoubiquitination) can variously activate or inhibit a protein's activity, while the attachment of a chain of multiple consecutively linked ubiquitin molecules (polyubiquitination) commonly targets the protein for degradation by proteasomes.
=== 2024: United Cup champion, two Masters titles and French Open final === Alongside Team Germany, Zverev competed and won the United Cup, saving two championship points in his singles match against Hubert Hurkacz and defeating Team Poland in the final. In Melbourne, he reached the quarterfinals of the 2024 Australian Open, defeating Dominik Koepfer, Lukas Klein for his 400th career win, Alex Michelsen, and Cameron Norrie, with two matches requiring deciding set tiebreakers. He then achieved his first-ever win against a top-5 player at a Grand Slam, defeating Carlos Alcaraz in four sets in the quarterfinals, to make his first Australian Open semifinal appearance since 2020. He subsequently lost to Danill Medvedev, despite being two sets to love up. His defeat marked only his second loss from being up two sets to love in a 5-set match, his first being against Dominic Thiem in the final of the 2020 US Open. In Mexico, Zverev reached the semifinals in Los Cabos with straight sets wins against Yoshihito Nishoka and Thanasi Kokkinakis but lost to Jordan Thompson in a deciding set tiebreaker. In Acapulco, Zverev lost to Daniel Altmaier in the first round. Seeded sixth at the BNP Paribas Open, Zverev reached the quarterfinals for the first time since 2021, defeating Christopher O'Connell, Tallon Griekspoor, and Alex de Minaur before losing to eventual champion Carlos Alcaraz. Seeded fourth at the Miami Open, Zverev reached the semifinals, defeating Félix Auger-Aliassime, Christopher Eubanks, Karen Khachanov, and Fábián Marozsán before losing to Grigor Dimitrov.
Sources: en.wikipedia.org
A GGT test is predominantly used as a diagnostic marker for liver disease. Elevated serum GGT activity can be found in diseases of the liver, biliary system, pancreas and kidneys. Latent elevations in GGT are typically seen in patients with chronic viral hepatitis infections often taking 12 months or more to present. Individual test results should always be interpreted using the reference range from the laboratory that performed the test, though example reference ranges are 15–85 IU/L for men, and 5–55 IU/L for women. GGT is similar to alkaline phosphatase (ALP) in detecting disease of the biliary tract. Indeed, the two markers correlate well, though there are conflicting data about whether GGT has better sensitivity. In general, ALP is still the first test for biliary disease. The main value of GGT is in verifying that ALP elevations are, in fact, due to biliary disease; ALP can also be increased in certain bone diseases, but GGT is not.
Bulk pharmaceuticals can be shipped to another pharmaceutical company for further processing, to a contract packager for forming unit packs, to international customers, etc. Bulk shipments might be in fiber drums (with plastic liners), bulk boxes, corrugated boxes with liners, intermediate bulk containers, and other shipping containers. Smaller bulk packs can be shipped to pharmacies, particularly compounding pharmacies. The liquids or powders can be measured and put into primary packages. Shipments to medical professionals could be at hospitals, nursing homes, veterinarians, dentists, etc. These packaged pharmaceuticals are intended to be dispensed and administered by professionally trained and certified personnel.
Chemical synthesis, either from petrochemical starting materials or from natural products extracts. Biotechnology, specifically biocatalysis (enzymatic methods) and biosynthesis (fermentation) for small molecules, and cell culture technology for big molecules. Extraction from animals, microorganisms, or plants; for example, isolation and purification is used for alkaloids, antibacterials (especially penicillins), and steroids. Hydrolysis of proteins, especially when combined with ion exchange chromatography, used, for instance, for amino acids. Chemical synthesis and biotechnology are most frequently used, sometimes in combination.
Sources: en.wikipedia.org
AOD-9604 is a synthetic peptide fragment of human growth hormone. It corresponds to the C-terminal region known as hGH 176-191 and is studied for metabolic effects. It is not an approved therapeutic drug.
No. It contains only a small portion of the human growth hormone sequence. The full hormone has 191 amino acids and many additional actions that the fragment does not share.
The name refers to the amino acid positions in the human growth hormone chain. The fragment spans residues 176 through 191 at the C-terminal end. This naming convention helps distinguish it from full-length hGH.
No. It is a synthetic peptide fragment modeled on part of human growth hormone, not the full hormone. It does not contain the complete sequence or receptor-binding regions of hGH.